Little is known about the malignant potential of mesenchymal tumors carrying rearrangements of the NFATC2, since even if reported and studied at the molecular level, the more detailed information of clinical course is given only for very few patients [12, 13, 20, 22–24, 26–30]. This evidence concerns the gene NFATC2 and mesenchymal cell neoplasm.